Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001093189 | SCV001250047 | pathogenic | not provided | 2019-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001093189 | SCV001392766 | pathogenic | not provided | 2023-11-24 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 2 of the RARS2 gene. It does not directly change the encoded amino acid sequence of the RARS2 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs63749985, gnomAD 0.003%). This variant has been observed in individuals with pontocerebellar hypoplasia (PMID: 17847012, 26970947). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS2+5A>G. ClinVar contains an entry for this variant (Variation ID: 891). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in exon 2 skipping and introduces a premature termination codon (PMID: 17847012). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000000939 | SCV002779363 | pathogenic | Pontocerebellar hypoplasia type 6 | 2022-04-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000000939 | SCV004208435 | pathogenic | Pontocerebellar hypoplasia type 6 | 2023-07-25 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000000939 | SCV000021089 | pathogenic | Pontocerebellar hypoplasia type 6 | 2007-10-01 | no assertion criteria provided | literature only |